Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT

Bone Marrow Transplantation volume 47, pages 499–507 (2012)Cite this article

Abstract

To evaluate the prognostic significance of Wilms’ tumor gene 1 (WT1) expression for monitoring minimal residual disease and predicting relapse in patients with acute leukemia (AL) following allogeneic hematopoietic SCT (allo-HSCT), the WT1 expression levels of 138 AL patients were measured using real-time quantitative reverse transcription PCR at designed time points after allo-HSCT. All patients were divided into four groups based on the HSCT outcomes and intervention application. A low level of WT1 expression following HSCT indicated a low risk of relapse, whereas WT1 expression >1.05% was indicative of a higher probability of relapse. Only the advanced stage of disease (hazard ratio (HR)=2.73; 95% confidence interval (CI)=1.337–5.573, P=0.006) and a WT1 expression ⩾0.60% (HR=4.774; 95% CI=2.410–9.459, P=0.000) were associated with lower disease-free survival. Relapse (HR=0.119; 95% CI=0.056–0.250, P=0.000) and a WT1 expression ⩾0.60% (HR=2.771; 95% CI=1.316–5.834, P=0.007) were associated with lower OS. In conclusion, the WT1 expression level is an independent prognostic factor that can predict clinical outcomes for AL patients after HSCT and provide a guide for suitable interventions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.

    CAS  PubMed  Google Scholar 

  2. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L . The expression of the Wilms’ tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2138–2143.

    CAS  PubMed  Google Scholar 

  3. Ogawa H, Ikegame K, Kawakami M, Tamaki H . WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk Lymphoma 2004; 45: 1747–1753.

    Article  CAS  PubMed  Google Scholar 

  4. Gianfaldoni G, Mannelli F, Ponziani V, Longo G, Bencini S, Bosi A et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010; 95: 833–836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hamalainen MM, Kairisto V, Juvonen V, Johansson J, Auren J, Kohonen K et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008; 80: 201–207.

    Article  PubMed  Google Scholar 

  6. Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009; 33: 384–390.

    Article  CAS  PubMed  Google Scholar 

  7. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507–1515.

    Article  CAS  PubMed  Google Scholar 

  8. Uzunel M, Ringden O . Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 47–52.

    Article  CAS  PubMed  Google Scholar 

  9. Imashuku S, Terui K, Matsuyama T, Asami K, Tsuchiya S, Ishii E et al. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant 2003; 31: 1127–1135.

    Article  CAS  PubMed  Google Scholar 

  10. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.

    Article  CAS  PubMed  Google Scholar 

  11. Candoni A, Toffoletti E, Gallina R, Simeone E, Chiozzotto M, Volpetti S et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011; 25: 308–316.

    Article  CAS  PubMed  Google Scholar 

  12. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  PubMed  Google Scholar 

  13. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.

    Article  CAS  PubMed  Google Scholar 

  14. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349–356.

    Article  CAS  PubMed  Google Scholar 

  15. Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y et al. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30: 317–323.

    Article  CAS  PubMed  Google Scholar 

  16. Simpson E, Matsunaga T . Physiological function of major histocompatibility complex macromolecules. Facts and hypotheses. Transplantation 1979; 27: 295–297.

    Article  CAS  PubMed  Google Scholar 

  17. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  18. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  PubMed  Google Scholar 

  19. Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28: 276–283.

    Article  CAS  PubMed  Google Scholar 

  20. Candoni A, Tiribelli M, Toffoletti E, Cilloni D, Chiarvesio A, Michelutti A et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009; 82: 61–68.

    Article  CAS  PubMed  Google Scholar 

  21. Busse A, Gokbuget N, Siehl JM, Hoelzer D, Schwartz S, Rietz A et al. Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 2009; 88: 1199–1205.

    Article  CAS  PubMed  Google Scholar 

  22. Gu WY, Chen ZX, Hu SY, Zhu J, Wang ZL, Yan F et al. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation]. Zhonghua yi xue za zhi 2005; 85: 444–447.

    CAS  PubMed  Google Scholar 

  23. Lasa A, Carricondo M, Estivill C, Bussaglia E, Gich I, Brunet S et al. WT1 monitoring in core binding factor AML: comparison with specific chimeric products. Leuk Res 2009; 33: 1643–1649.

    Article  CAS  PubMed  Google Scholar 

  24. Lin F, van Rhee F, Goldman JM, Cross NC . Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473–4478.

    CAS  PubMed  Google Scholar 

  25. Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haemat 2009; 146: 669–674.

    Article  CAS  Google Scholar 

  26. Jin S, Liu DH, Xu LP, Chen H, Chen YH, Qin YZ et al. [The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation]. Zhonghua nei ke za zhi [Chin J Intern Med] 2008; 47: 578–581.

    Google Scholar 

Download references

Acknowledgements

This work was supported by the National Outstanding Young Scientist's Foundation of China (grant no. 30725038), the Program for Innovative Research Team in University (grant no. IRT 0702) and the Leading Program of Clinical Faculty accredited by the Ministry of Health of China.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, People's Hospital, Peking University Institute of Hematology, Beijing, China

    X-S Zhao, S Jin, H-H Zhu, L-P Xu, D-H Liu, H Chen, K-Y Liu & X-J Huang

Authors
  1. X-S Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H-H Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L-P Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D-H Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K-Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. X-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, XS., Jin, S., Zhu, HH. et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 47, 499–507 (2012). https://doi.org/10.1038/bmt.2011.121

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.121

Keywords

This article is cited by

Search

Advanced search

Quick links